Company news
Halozyme Therapeutics, Inc. news in 2021
Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Halozyme appoints new general counsel
December 12, 2021
Halozyme announces $750 million three-year share repurchase program
December 8, 2021
Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
November 30, 2021
Halozyme Reports Third Quarter 2021 Results
November 1, 2021
Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call
October 18, 2021
Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 14, 2021
Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference
August 25, 2021
Halozyme Reports Second Quarter 2021 Results
August 8, 2021
Halozyme to Participate in Canaccord Genuity 41st Annual Growth Conference
July 29, 2021
Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference Call
July 26, 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
June 21, 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
June 21, 2021
Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple Myeloma
June 21, 2021
Halozyme Highlights Data Presentations by Collaborators for Therapies Utilizing ENHANZE® at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2021
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®
May 20, 2021
Halozyme Reports First Quarter 2021 Results
May 9, 2021
Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference
April 28, 2021
Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call
April 19, 2021
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027
February 23, 2021
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
February 22, 2021
Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results
February 22, 2021
Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
February 9, 2021
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis
January 14, 2021
Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth
January 10, 2021
Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference
January 3, 2021
Calls in 2021
- Halozyme Therapeutics (NASDAQ:HALO) Q3 2021 Earnings Call
Nov 2, 2021
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q2 2021 Earnings Call
Aug 9, 2021
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q1 2021 Earnings Call
May 10, 2021
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q4 2020 Earnings Call
Feb 23, 2021
Transcript
Decks in 2021
- Q3 2021 Earnings Presentation
Earnings · 15 slides · Nov 2, 2021
- Q2 2021 Earnings Presentation
Earnings · 16 slides · Aug 9, 2021
- Q1 2021 Earnings Presentation
Earnings · 14 slides · May 5, 2021
- Q4 2020 Earnings Presentation
Earnings · 13 slides · Feb 23, 2021
- 39th Annual J.P. Morgan Healthcare Conference (January 2021)
Conference · 33 slides · Jan 13, 2021